WallStreetZenWallStreetZen

NASDAQ: RGEN
Repligen Corp Stock Forecast, Predictions & Price Target

Analyst price target for RGEN

Based on 5 analysts offering 12 month price targets for Repligen Corp.
Min Forecast
$185.00+16.34%
Avg Forecast
$197.20+24.02%
Max Forecast
$210.00+32.07%

Should I buy or sell RGEN stock?

Based on 5 analysts offering ratings for Repligen Corp.
Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RGEN stock forecasts and price targets.

RGEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
RBC Capital
Bottom 4%
4
BuyReiterates$191.00+20.12%2023-09-08
Craig-Hallum
Bottom 8%
8
BuyMaintains$200.00+25.78%2023-08-03
Stephens & Co.
Bottom 9%
9
Strong BuyMaintains$200.00+25.78%2023-08-03
Wells Fargo
Bottom 27%
27
Strong BuyInitiates Coverage On$185.00+16.34%2023-07-20
Stifel Nicolaus
Top 13%
88
Strong BuyMaintains$210.00+32.07%2023-05-03

1 of 1

Forecast return on equity

Is RGEN forecast to generate an efficient return?
Company
13.72%
Industry
20.64%
Market
58.05%
RGEN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RGEN forecast to generate an efficient return on assets?
Company
10.61%
Industry
11.16%
RGEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RGEN earnings growth forecast

How is RGEN forecast to perform vs Medical Instruments & Supplies companies and vs the US market?
Company
31.3%
Industry
45.58%
Market
21.9%
RGEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
RGEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
RGEN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

RGEN revenue growth forecast

How is RGEN forecast to perform vs Medical Instruments & Supplies companies and vs the US market?
Company
22.36%
Industry
5.51%
Market
7.96%
RGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RGEN vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
RGEN$159.01$197.20+24.02%Strong Buy
STVN$29.72$35.00+17.77%Strong Buy
TFX$196.41$279.86+42.49%Buy
ATR$125.04$140.75+12.56%Strong Buy
XRAY$34.16$44.80+31.15%Buy

Repligen Stock Forecast FAQ

Is Repligen Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: RGEN) stock is to Strong Buy RGEN stock.

Out of 5 analysts, 3 (60%) are recommending RGEN as a Strong Buy, 2 (40%) are recommending RGEN as a Buy, 0 (0%) are recommending RGEN as a Hold, 0 (0%) are recommending RGEN as a Sell, and 0 (0%) are recommending RGEN as a Strong Sell.

If you're new to stock investing, here's how to buy Repligen stock.

What is RGEN's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: RGEN) forecast ROE is 13.72%, which is considered weak.

What is RGEN's Price Target?

According to 5 Wall Street analysts that have issued a 1 year RGEN price target, the average RGEN price target is $197.20, with the highest RGEN stock price forecast at $210.00 and the lowest RGEN stock price forecast at $185.00.

On average, Wall Street analysts predict that Repligen's share price could reach $197.20 by Sep 8, 2024. The average Repligen stock price prediction forecasts a potential upside of 24.02% from the current RGEN share price of $159.01.

What is RGEN's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: RGEN) forecast ROA is 10.61%, which is lower than the forecast US Medical Instruments & Supplies industry average of 11.16%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.